153 related articles for article (PubMed ID: 10023504)
1. Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable?
Mundo E; Bareggi SR; Pirola R; Bellodi L
Biol Psychiatry; 1999 Feb; 45(3):290-4. PubMed ID: 10023504
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
Mundo E; Bianchi L; Bellodi L
J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005
[TBL] [Abstract][Full Text] [Related]
3. Effects of acute intravenous clomipramine on obsessive-compulsive symptoms and response to chronic treatment.
Mundo E; Bellodi L; Smeraldi E
Biol Psychiatry; 1995 Oct; 38(8):525-31. PubMed ID: 8562664
[TBL] [Abstract][Full Text] [Related]
4. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.
Koran LM; McElroy SL; Davidson JR; Rasmussen SA; Hollander E; Jenike MA
J Clin Psychopharmacol; 1996 Apr; 16(2):121-9. PubMed ID: 8690827
[TBL] [Abstract][Full Text] [Related]
5. Clinical predictors of drug response in obsessive-compulsive disorder.
Erzegovesi S; Cavallini MC; Cavedini P; Diaferia G; Locatelli M; Bellodi L
J Clin Psychopharmacol; 2001 Oct; 21(5):488-92. PubMed ID: 11593074
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
Piccinelli M; Pini S; Bellantuono C; Wilkinson G
Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913
[TBL] [Abstract][Full Text] [Related]
7. Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study.
Mundo E; Bareggi SR; Pirola R; Bellodi L; Smeraldi E
J Clin Psychopharmacol; 1997 Feb; 17(1):4-10. PubMed ID: 9004050
[TBL] [Abstract][Full Text] [Related]
8. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions.
Goodman WK; Ward H; Kablinger A; Murphy T
J Clin Psychiatry; 1997; 58 Suppl 5():32-49. PubMed ID: 9184625
[TBL] [Abstract][Full Text] [Related]
9. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.
Milanfranchi A; Ravagli S; Lensi P; Marazziti D; Cassano GB
Int Clin Psychopharmacol; 1997 May; 12(3):131-6. PubMed ID: 9248868
[TBL] [Abstract][Full Text] [Related]
10. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory.
Jenike MA; Hyman S; Baer L; Holland A; Minichiello WE; Buttolph L; Summergrad P; Seymour R; Ricciardi J
Am J Psychiatry; 1990 Sep; 147(9):1209-15. PubMed ID: 2143637
[TBL] [Abstract][Full Text] [Related]
11. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study.
Fallon BA; Liebowitz MR; Campeas R; Schneier FR; Marshall R; Davies S; Goetz D; Klein DF
Arch Gen Psychiatry; 1998 Oct; 55(10):918-24. PubMed ID: 9783563
[TBL] [Abstract][Full Text] [Related]
12. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
Pigott TA; Seay SM
J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
[TBL] [Abstract][Full Text] [Related]
13. Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder.
Zitterl W; Aigner M; Stompe T; Zitterl-Eglseer K; Gutierrez-Lobos K; Wenzel T; Zettinig G; Hornik K; Pirker W; Thau K
Neuropsychopharmacology; 2008 Dec; 33(13):3126-34. PubMed ID: 18354388
[TBL] [Abstract][Full Text] [Related]
14. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
15. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment.
Zohar J; Insel TR; Zohar-Kadouch RC; Hill JL; Murphy DL
Arch Gen Psychiatry; 1988 Feb; 45(2):167-72. PubMed ID: 3276283
[TBL] [Abstract][Full Text] [Related]
16. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study.
Mundo E; Guglielmo E; Bellodi L
Int Clin Psychopharmacol; 1998 Sep; 13(5):219-24. PubMed ID: 9817627
[TBL] [Abstract][Full Text] [Related]
17. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
[TBL] [Abstract][Full Text] [Related]
18. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder.
Koran LM; Sallee FR; Pallanti S
Am J Psychiatry; 1997 Mar; 154(3):396-401. PubMed ID: 9054789
[TBL] [Abstract][Full Text] [Related]
19. Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.
Mundo E; Maina G; Uslenghi C
Int Clin Psychopharmacol; 2000 Mar; 15(2):69-76. PubMed ID: 10759337
[TBL] [Abstract][Full Text] [Related]
20. Obsessive-compulsive disorder as a 5-HT subsystem-related behavioural disorder.
Murphy DL; Zohar J; Benkelfat C; Pato MT; Pigott TA; Insel TR
Br J Psychiatry Suppl; 1989 Dec; (8):15-24. PubMed ID: 2692636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
